Improvement of quality of life and menopausal symptoms in climacteric women treated with low-dose monthly parenteral formulations of non-polymeric microspheres of 17β-estradiol/progesterone

Objective: To evaluate the short term effect over menopausal symptoms and quality of life (QoL) of monthly parenteral formulations of 17b-estradiol (E)/progesterone (P) non-polymeric microspheres. Methods: This is a secondary analysis of a multicenter, randomized, single-blinded study that included peri-and post-menopausal symptomatic women assigned to receive a monthly intramuscular injection of 0.5mg E + 15mg P (Group A, n = 34), 1mg E + 20mg P (Group B, n = 24), or 1mg E + 30mg P (Group C, n = 26) for 6 months. Intensity of menopausal symptoms was assessed before and after treatment with the Greene Climacteric Scale (GCS) and QoL with the Utian Quality of Life Scale (UQoLS). Results: Menopausal symptoms improved for all groups at six months evidenced by lower cluster/sub-cluster GCS scores. Equally, there was an overall trend for QoL improvement for all groups evidenced by higher domain UQoLS scores at six months; but only significant for the emotional (Groups A and B) and occupational domains (Groups A and C). Conclusion: The three low-dose continuous sequential intramuscular monthly formulations of E/P microspheres exerted a positive effect over menopausal symptoms and QoL. Long-term research is warranted with these formulations.